FOLLICULAR LYMPHOMA

This study compares standard radiation (24 Gy) to a very low dose (4 Gy) for people with follicular or marginal zone lymphoma. The goal is to see if the low dose works just as well but causes fewer side effects. About 375 participants will be enrolled, and the study is currently …

This study tests a new vaccine (EO2463) designed to train the immune system to attack lymphoma cells. It is for people with follicular or marginal zone lymphoma, either newly diagnosed or after prior treatment. The vaccine is given alone or with standard drugs lenalidomide and ri…

This study tests a combination of two drugs, epcoritamab and rituximab, as the first treatment for people with follicular lymphoma, a slow-growing blood cancer. About 100 adults who have not had prior lymphoma therapy will receive the drugs to see how well they shrink tumors and …

This early-phase trial tests an oral drug called AS-1763 in adults with certain blood cancers (like CLL or lymphoma) that have not responded to at least two prior treatments. The main goals are to find the safest dose and see if the drug can shrink tumors. Around 120 participants…

This study offers ongoing access to the drug ibrutinib for people with certain blood cancers (like chronic lymphocytic leukemia or mantle cell lymphoma) who are already taking it and benefiting. Researchers will track side effects and disease changes over time. About 700 particip…

This study looks at how well the drug epcoritamab works for people with advanced types of lymphoma (DLBCL and FL) in everyday medical practice. About 700 adults who are already scheduled to receive this drug will be followed for up to 3 years. The goal is to see how many patients…

This early-phase study tests a new drug, ONM-501, injected directly into tumors, either alone or with another drug (cemiplimab), in people with advanced solid tumors or lymphomas that have not responded to other treatments. The main goals are to find the safest dose and understan…

This study tests whether the drug mosunetuzumab, given alone or with zanubrutinib, can effectively treat people who have just been diagnosed with follicular lymphoma and need therapy. About 152 adults with stage II to IV lymphoma will receive the treatment to see if it causes the…

This early-phase study tests a new drug called AZD0486 in about 227 people with B-cell non-Hodgkin lymphoma, including types like diffuse large B-cell and follicular lymphoma. The drug is a special antibody that helps the immune system attack cancer cells. The main goals are to c…

This early-phase study is testing an experimental oral drug called LP-168 in about 60 people with certain blood cancers (like CLL, lymphoma, and Waldenstrom macroglobulinemia) that have returned or not responded to prior therapies. The main goals are to find the safest dose and u…

This early-phase study tests a new drug called SGR-1505 in about 98 adults with various B-cell blood cancers (like lymphoma and leukemia). The main goals are to check safety and find the best dose. Participants will receive the drug and be monitored for side effects and how the d…

This study tests whether a combination of two drugs (orelabrutinib and rituximab) followed by maintenance with orelabrutinib can shrink tumors or slow disease in people with follicular lymphoma that has come back or not responded to prior treatment. About 32 adults will receive t…

This study is for people with B-cell blood cancers like lymphoma and leukemia. It tests a new drug, BGB-16673, that breaks down a protein helping cancer grow. The goal is to find the right dose and see if it is safe and shrinks tumors. About 146 people in China will take part.

This study tests whether the drug epcoritamab can help people with follicular lymphoma whose cancer did not completely go away after their first chemotherapy and immunotherapy treatment. About 35 adults with advanced-stage lymphoma will receive epcoritamab as a second treatment. …

This study tests a drug called odronextamab in 35 people with untreated, low-tumor follicular lymphoma. The goal is to see if it can shrink or eliminate cancer without needing standard chemotherapy. Participants receive the drug and are monitored for safety and response.

This early-phase study tests a new type of CAR T cell therapy that targets two proteins (CD79b and CD19) on lymphoma cells. It is for people with non-Hodgkin lymphoma that has come back or not responded to standard treatments. The main goals are to check safety and find the right…

This study tests a new treatment for people with certain types of lymphoma or leukemia that have come back or not responded to standard therapy. The treatment uses the patient's own immune cells (T cells) that are modified in a lab to recognize and attack cancer cells. The main g…

This study tests a new treatment called CTX112 for people with B-cell blood cancers (like lymphoma or leukemia) that have come back or not responded to standard therapy. CTX112 uses CRISPR gene-editing to create donor T-cells that target and kill cancer cells. The trial involves …

This early-phase study tests a new treatment called SynKIR-310 for adults with B-cell non-Hodgkin lymphoma that has come back or not responded to at least two prior therapies. The treatment uses a patient's own immune cells, modified to recognize and attack cancer cells. The main…

This early-stage study tests a new gene therapy called VNX-101 for people with certain blood cancers (like leukemia and lymphoma) that have returned or not improved with standard treatments. The therapy uses a harmless virus to deliver a gene that helps the immune system attack c…

This study is for people with certain types of B-cell or Hodgkin lymphoma. Participants first get a stem cell transplant using their own cells, then receive a targeted drug called polatuzumab vedotin every 3 weeks for up to 8 doses. The goal is to see if this approach is safe and…

This early-phase study tests whether a personalized cell therapy (CAR-T cells) is safe for people with certain types of Non-Hodgkin lymphoma that have come back or not responded to standard treatments. Up to 36 participants will receive their own immune cells that have been genet…

This study tests an experimental drug called BGB-16673 in people with several types of B-cell cancers (like lymphoma and leukemia) that have come back or not responded to other treatments. The drug works by breaking down a protein (BTK) that helps these cancer cells grow. The tri…

This study tests a two-drug combination (mosunetuzumab and lenalidomide) as the first treatment for adults with follicular or marginal zone lymphoma. Participants start with mosunetuzumab alone, then add lenalidomide if the cancer only partially responds. The goal is to see how m…

This study tests whether a new drug called golcadomide combined with rituximab works better than standard treatments for people with follicular lymphoma that has come back or stopped responding to therapy. About 400 adults who have already had at least one prior treatment will be…

This study tests whether the drug emapalumab can prevent severe cytokine release syndrome (CRS), a common and serious side effect of CAR-T cell therapy, in adults with certain types of non-Hodgkin lymphoma that have come back or not responded to treatment. About 28 participants w…

This study tests a combination of three drugs (zanubrutinib, obinutuzumab, and lenalidomide) in people with untreated follicular lymphoma, a type of blood cancer. The goal is to see how well the treatment shrinks or controls the cancer. About 34 adults with stage II bulky or stag…

This study tests whether combining two drugs—loncastuximab tesirine and rituximab—can make follicular lymphoma disappear completely in people whose cancer returned or didn't respond to prior treatment. About 100 adults will receive the combo and be checked at 12 weeks. The goal i…

This early-stage study tests an experimental drug called ABBV-319 in adults with B-cell lymphomas or chronic lymphocytic leukemia that has come back or not responded to treatment. The main goals are to check safety, find the right dose, and see if the drug shrinks tumors. About 1…

This study offers a special CAR T-cell treatment called axicabtagene ciloleucel to people with large B-cell or follicular lymphoma whose commercial batch didn't pass quality checks. Participants must meet safety criteria and have no other good options. The goal is to provide acce…

This study tests a combination of a CAR T-cell therapy (axicabtagene ciloleucel) and radiation in people with follicular lymphoma that has come back or not responded to at least two prior treatments. The goal is to see if adding radiation makes the cell therapy safer and more eff…

This study tests a combination of two drugs, mosunetuzumab and zanubrutinib, in people with follicular lymphoma that has come back or not responded to prior treatment. The goal is to see if this combination can shrink or eliminate tumors. About 56 adults will receive the treatmen…

This early-stage trial tests a new drug called IKS03 in people with advanced B-cell non-Hodgkin lymphoma that has not responded to other treatments. IKS03 is an antibody-drug conjugate designed to deliver a toxic payload directly to cancer cells. The study aims to find the safest…

This study is testing whether a combination of two drugs, rituximab and zanubrutinib, is safe and works well for people with untreated follicular lymphoma or marginal zone lymphoma. About 43 adults will take both drugs and be monitored for response and side effects. The goal is t…

This early-phase study tests a new treatment for adults with B-cell blood cancers (like lymphoma) that have not responded to prior therapies. Participants receive a special type of immune cell (CAR T-cells) along with a targeted drug called pirtobrutinib, which is given before an…

This study is testing an experimental drug called LY4584180 in adults with certain blood cancers (like lymphoma) that have not improved after at least two prior treatments. The main goals are to check the drug's safety, how the body processes it, and whether it can shrink tumors.…

This study is for people with early-stage follicular lymphoma, a slow-growing blood cancer. It compares standard radiation therapy alone to radiation plus a drug called obinutuzumab. The goal is to see if adding the drug helps keep the cancer from coming back longer. About 190 pa…

This study tests a new type of CAR-T cell therapy that targets two proteins (CD19 and CD20) on cancer cells, aiming to treat adults with B-cell blood cancers like lymphoma and leukemia that have not responded to other treatments. The therapy uses the patient's own immune cells, w…

This study tests a combination of three drugs—epcoritamab, zanubrutinib, and rituximab—in people with follicular lymphoma or marginal zone lymphoma that has come back or not responded to prior treatment. The goal is to see how well the combo works at shrinking tumors and to check…

This study tests a new type of PET/CT scan that looks for a protein called CD70 on cancer cells. It aims to better detect kidney cancer, lymphoma, and nasopharyngeal cancer in 300 adults. The scan may help doctors see tumors more clearly and guide treatment decisions.

This study looks at how the body processes venetoclax when the tablets are crushed and mixed into a liquid for children and young adults with blood cancers like leukemia or lymphoma. About 30 participants who already take venetoclax this way will have their blood levels measured.…

This study is for adults with untreated follicular lymphoma, a type of lymph node cancer. Researchers will collect blood, tissue, and other samples over several years to learn how the disease progresses and responds to treatment. The goal is to gather information that could help …

This study analyzes stored blood and tissue samples from 654 people with follicular lymphoma to investigate genetic changes (EZH2 and others) and how they relate to treatment outcomes. The goal is to learn more about the disease, not to test a new treatment. Participants are from…

This study is testing whether an artificial intelligence tool can help match cancer patients to clinical trials they might be eligible for. Researchers will enroll up to 50,000 people with various types of cancer and use the AI to suggest trials. The goal is to see if this approa…

This study looks at whether CAR-T cell therapy, a treatment for certain blood cancers, reduces the protection that past vaccines (like measles or tetanus shots) provide. Researchers will test the blood of 45 adults with multiple myeloma or non-Hodgkin lymphoma before and after CA…

This study looks at how the immune system of people with lymphoma responds to flu and COVID vaccines. Researchers will measure antibody levels and immune cells in 200 participants with different types of lymphoma and compare them to healthy individuals. The goal is to understand …

This study is observing adults with Waldenström's macroglobulinemia, chronic lymphocytic leukemia, marginal zone lymphoma, or follicular lymphoma who are taking the drug zanubrutinib. Researchers want to see how often patients need hospital care and how their quality of life chan…

This study follows up to 500 people who received CAR-T cell therapy for blood cancers like leukemia, lymphoma, or multiple myeloma. Researchers will track participants for up to 15 years to see if any new cancers develop. The goal is to understand the long-term safety of this tre…